Navigation Links
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo

significance. For TST, the 50 mg dose achieved significance (p=0.024) and the 20 and 100 mg doses showed a trend toward significance.

"VEC-162 induces and maintains sleep by modulating the sleep/wake cycle," said Paolo Baroldi, M.D., Ph.D., Chief Medical Officer, Vanda Pharmaceuticals Inc. "The subjective findings suggest the compound's unique mechanism of action provides a noticeable improvement in overall sleep quality."

About Insomnia

Approximately 70 million American adults experience insomnia of all types, characterized by difficulty falling asleep, waking frequently during the night, waking too early and not being able to return to sleep, or waking up not feeling refreshed. Circadian Rhythm Sleep Disorders (CRSD), one type of insomnia, affect millions of Americans in a number of forms. Shift Worker Sleep Disorder is a CRSD affecting the 14% of Americans who are shift workers. Another CRSD type is Delayed Sleep Phase Syndrome, which affects 5-10% of patients in sleep disorder clinics and accounts for 40% of disorders involving sleep-wake schedules.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., headquartered in Rockville, Maryland, is a biopharmaceutical company working to advance the science of personalized medicine to improve the lives of patients with various CNS disorders, including insomnia and schizophrenia. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and has completed its Phase III program. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound in Phase II for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com .

N
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

Post Your Comments:
(Date:11/27/2009)... , SALT LAKE CITY, Nov. 27 /PRNewswire-Firs...al Systems, Inc. (NYSE: VAR ), a premier supplie...ctors, will exhibit its full range of detectors at...ember 29 - December 3, 2009. Varian will also be ...lities as well as specialized cancer treatment tec...
(Date:11/26/2009)... , JOHANNESBURG, South Africa, Nov. 26 /PR...frica Company of the Year Award in the Generic Pha...uth Africa Limited. ,, (Logo: http://www.newsc...e Company of the Year Award, the following criteri...e against key competitors: growth strategy and imp...
(Date:11/25/2009)... , LOVELAND, Colo., Nov. 25 /PRNewswire-Fir... leading provider of advanced diagnostic and spe...ced today agreements with Roche Diagnostics Corpor...iliated consumables for the veterinary market. .../20000622/HESKALOGO ) ,, "Heska and Roche share...
Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Texas Doctor Files Case Pro Se in U S Supreme Court Against Insurance Giant on Integrity and Unethical Practices 58242 1Texas Doctor Files Case Pro Se in U S Supreme Court Against Insurance Giant on Integrity and Unethical Practices 58242 2Texas Doctor Files Case Pro Se in U S Supreme Court Against Insurance Giant on Integrity and Unethical Practices 58242 3New Cardiovascular Biomarker Available for Scientist in North America 5054 1New Cardiovascular Biomarker Available for Scientist in North America 5054 230th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 130th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 230th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 330th Anniversary Edition of Mandell Douglas and Bennetts Principles and Practice of Infectious Diseases is More Relevant Than Ever 58240 4
...Achieves Primary Endpoint Among High-Risk Infants ...n of Medically Attended,Outpatient RSV- Related Lo...7 /PRNewswire-FirstCall/ -- MedImmune, Inc.,today ...e trial,conducted for prevention of respiratory sy...b, the investigational monoclonal antibody,(MAb) a...
...D--(BUSINESS WIRE)--May 10, 2007 - An evaluation o...trogen therapy for the,treatment of vaginal atroph...as just been released by The North American,Menopa...ginal,estrogen for treatment of vaginal atrophy in...The North American Menopause Society,",the documen...
Other Medicine Technology:MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 2New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 3
(Date:11/28/2009)...eved to affect circadian rhythm, , ,... suggests that an internal body clock that goes on... bipolar disorder in children. , The finding r...of 152 children with bipolar disorder, which can m...40 children without the disorder. They linked vari...
(Date:11/27/2009)...v. 27 GSI Group Inc. (Pi...ecision technology products and semiconductor syst... Company,s shareholders has been scheduled for Fri... meeting will be announced in due course. As prev...on notice from Stephen Bershad, a holder of greate...
(Date:11/27/2009)...ch firm Replikins Ltd. today issued its latest bio... It shows that the lethality of the virus has drop...us,s current outbreak in the spring of 2009 to res...1). The H1N1 infectivity count, however, remains i...) November 27, 2009 -- Biotech firm Replikins Ltd....
(Date:11/27/2009)...27 The Gymboree Corporat... CFO/COO, will present at the NASDAQ OMX 23rd Inve...otel in London, England, on Wednesday, December 2,...e broadcast of The Gymboree Corporation,s presenta...ree.com, click on "Our Company" at the bottom of t...
(Date:11/27/2009)..., France, Nov. 27 Team Garmin-Slip...am dedicated to ethical sporting and developing th...today that it will become Team Garmin-Transitions ...sponsor of the team. Transitions Optical is the wo...fering the most advanced photochromic technology i...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3
...ults of their work linking mutations in BRAC2 gene...as published in the Journal of Medical Ethics. //M...velopment of breast and ovarian cancer in women ha...n BRAC2 mutations and increased risk of developmen...
...icking up infections like MRSA if they glucose in ...the recent issue of the journal Thorax.// The...ically ill patients in intensive care who required...re measured in their blood samples and lung secret...
...tterns associated with amusia or tone deafness in ...with other learning disorders like dyslexia. // ..., people who are tone deaf -- in scientific terms,...ired following injury to the brain. In an a...
...red to as meconium aspiration) occurs when a newbo...d during labor and delivery. Meconium is the m...ng pregnancy and is formed from ingested amniotic ...It can cause a partial or complete blockage of the...
...ncet, have proposed treating burst aneurysms with ...2002 the International Subarachnoid Aneurysm Trial...he minimally invasive technique, coiling, was more...ves a craniotomy and clipping of the aneurysm to s...
...ctrons have been implicated in a number of degener...mmunity has been trying hard to protect the body f...mentation with anti-oxidants, substances that coun...could help fight chronic disease. Numerous st...
Other Medicine News:Health News:Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions 2Health News:Platinum Coils To Replace Brain Surgery 2
...gital offers improved ergonomics for today's exact...ied grippy finger rest and the large display windo...pette Digitals also feature soft-touch tip ejectio...) and super blow-out for 0.2 - 50ul micro volume p...
...0i is the first Sysmex hematology analyzer designe...ents. With its small footprint, closed tube sampli...ole blood sample, you have a solution for any smal...rgical suite, or small clinic. The differential on...
...aker family, which includes the world's smallest d...e most advanced pacemaker technology available, in..., the first and only U.S. commercially approved al...AF). The AF Suppression algorithm in the Identity ...
IntelliVue Information Center
Medicine Products: